Cancer Detection

SpectRx completes milestone clinical study of new noninvasive cervical cancer device

Published in Cancer Weekly, December 10th, 2002

SpectRx, Inc., (SPRX) announced that it has completed the multicenter, prepivotal clinical trial of its noninvasive cervical cancer detection device, and the company is making final preparations to begin its FDA pivotal trial.

Analysis of results from the first 414 women in the prepivotal study indicates that the SpectRx device detected 16% more high-grade precancers than Pap tests, the majority of which were the thin layer Pap tests. These results suggest that the SpectRx device could reduce by more than half the 2.2 million unnecessary follow up colposcopic exams and 1.6 million unnecessary biopsies resulting from uncertain or false positive Pap test results. In the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry